Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Alicia Llorente and coworkers from the Department of Molecular Cell Biology at the Institute for Cancer Research recently published in Oncotarget detailed mass spectrometry analyses of exosomes purified from urine of 16 prostate cancer patients and 15 healthy volunteers that revealed upregulation of 221 proteins in the patient samples. At 100% specificity, 17 of these proteins displayed individual sensitivities between 60 and 94%. Combination of two of the upregulated proteins (TM256 and LAMTOR1) resulted in 100% specificity and 100% sensitivity for these samples.
The Norwegian Advanced Light Microscopy Imaging Network, NALMIN, coordinated by Harald Stenmark at Institute for Cancer Research and Centre for Cancer Biomedicine, has been funded by 49.5 MNOK by the Research Council of Norway. This is good news for Norwegian researchers who use light microscopy in their studies.
Bjarne Johannessen and Rolf Skotheim from the Department of Molecular Oncology at the Institute for Cancer Research have written about bioinformatics and big data challenges in cancer genomics. The popularized science article appeared as a cover story in the META magazine:
The META journal is published by UNINETT Sigma2, and the aim is to present research projects that are part of Notur and Norstore.
Professor Erik Fosse from The Intervention Centre at the Division of Diagnostics and Intervention, OUS, is awarded the University of Oslo Innovation prize for his creations within the fields of medicine and health service.
Fosse will receive the prize at a seremony taking place during the annual party for the University of Oslo September 2nd.
A recent Nature paper by Marina Vietri and colleagues in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Biomedicine has attracted considerable attention worldwide.
This paper, which shows a mechanism for nuclear envelope sealing during mitotic exit and its importance for genome integrity, has been dedicated commentary articles in both of the world's most influential scientific journals, Nature and Science. This is very unusual for cell biological papers and illustrates the impact of the findings by the Norwegian research group.
In an article for the OUS research blog published June 16th PhD student Tine Norman Alver from the Department of Tumor Biology at the Insitute for Cancer researchs discusses dilemmas and viewpoints around cost and payment of expensive cancer medicines and treatments, illustrated by some concrete recent cases from Norway. Her blog article (in Norwegian) is entitled "What is the cost of a cancer patient's life".
Jun 25, 2015
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Serologic Assay for Diagnosis of Celiac Disease Based on a Patient-derived Monoclonal Anti-gliadin Antibody
Gastroenterology (in press)
BayesPI-BAR: a new biophysical model for characterization of regulatory sequence variations
Nucleic Acids Res (in press)
More selected publications